Ansa Biotechnologies, Inc.
StreetZero Signal 81
About Ansa Biotechnologies, Inc.
Ansa Biotechnologies, Inc. is a biotechnology company developing enzymatic DNA synthesis technology and serving as a trusted partner for synthetic DNA production. It offers products including gene fragments up to 1 kb and emphasizes reliability with the industry’s first guaranteed on-time service. The company is headquartered in Emeryville, California, and focuses on enabling scientists to accelerate research by writing genomes rather than just reading them.
LATEST FUNDINGSeries B
$54.4M
Announced 2026-11-18
TOTAL RAISED$138.31M
IN THE NEWS
- 🔗 Ansa Biotechnologies Secures $54.4 Million in Series B Financing to Redefine How Scientists Access Synthetic DNA with Industry’s First Guaranteed On-Time Service - Cerberus Capital Management
- 🔗 Ansa Biotechnologies Funding, Investors & Competitors | Multiples
- 🔗 Ansa snares $54.4M in series B to boost its DNA synthesis platform
- 🔗 Ansa Biotechnologies, Inc.
- 🔗 Ansa Biotechnologies - Products, Competitors, Financials, Employees, Headquarters Locations
EMPLOYEES—
FOUNDED2018
HQEmeryville, California, United States
Industry
Biotechnology
Tags
BiotechnologyDNA SynthesisSeries BSynthetic Biology
Investors
Key highlights
- Raised $54.4M Series B in 2025 to expand DNA synthesis capacity and commercialization.
- Previously raised $68M Series A in April 2022 led by Northpond Ventures.
- Offers guaranteed on-time synthetic DNA delivery and aims to synthesize every customer sequence.
- Total funding reaches $138.31M with backing from Cerberus, RA Capital, and others.
Ask StreetZero about Ansa Biotechnologies, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account